The GLP-1 receptor agonist market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 to 2032 for the following segments: By Drug Class Semaglutide Dulaglutide Liraglutide Exenatide Other drug classes By Route of Administration Parenteral Oral By Application Type 2 diabetes mellitus Obesity Other applications By Distribution Channel Hospital pharmacies Retail pharmacies Online pharmacies The above information is provided for the following regions and countries: North America U.S
PubMed, Lee, Robert J., et al
Comparatively, tirzepatide, the active ingredient in Zepbound and Mounjaro, demonstrated an average weight loss of 22.9% at 176 weeks with the 15 mg dose in the SURMOUNT-1 Phase 3 study in adults with pre-diabetes and obesity or overweight
Separately, it lists situations where semaglutide is not appropriate at all: personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, or uncontrolled diabetic retinopathy
Use a different area of the abdomen or thigh each week